Get the Stockscreener App
175.21
1.20%
2.08
Pre-market:
176.01
0.80
+0.46%
Icon Plc stock is traded at $175.21, with a volume of 894.95K.
It is up +1.20% in the last 24 hours and down -0.36% over the past month.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
See More
Previous Close:
$173.13
Open:
$172.79
24h Volume:
894.95K
Relative Volume:
0.70
Market Cap:
$14.15B
Revenue:
$8.19B
Net Income/Loss:
$758.19M
P/E Ratio:
19.09
EPS:
9.18
Net Cash Flow:
$1.06B
1W Performance:
+5.91%
1M Performance:
-0.36%
6M Performance:
-5.68%
1Y Performance:
-40.11%
1-Day Range:
$172.79
$178.17
1-Week Range:
$166.40
$178.17
52-Week Range:
$125.10
$310.54
Icon Plc Stock (ICLR) Company Profile
Compare ICLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
175.21 | 13.46B | 8.19B | 758.19M | 1.06B | 9.18 |
|
TMO
Thermo Fisher Scientific Inc
|
472.64 | 181.53B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
192.94 | 136.39B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
640.86 | 51.66B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
126.72 | 36.06B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
186.69 | 31.76B | 15.70B | 1.24B | 2.01B | 6.91 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-03-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Aug-21-25 | Downgrade | Citigroup | Buy → Neutral |
| Jul-24-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
Mizuho Securities Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $225 - 富途牛牛
Goldman Sachs Group Inc. Sells 106,606 Shares of Icon Plc $ICLR - MarketBeat
Greenhaven Associates Inc. Acquires New Shares in Icon Plc $ICLR - MarketBeat
Icon Plc $ICLR Stake Decreased by LVM Capital Management Ltd. MI - MarketBeat
Did ICON’s (ICLR) Internal CEO Succession Signal Strategic Continuity or Missed Opportunity for Change? - simplywall.st
Jefferies rates IQVIA, Charles River as Buy, ICON as Hold - MSN
Brokerages Set Icon Plc (NASDAQ:ICLR) PT at $219.64 - MarketBeat
Jefferies Downgrades ICON Public Limited (ICLR) to Hold From Buy - Insider Monkey
TD Cowen Maintains Icon PLC(ICLR.US) With Hold Rating, Cuts Target Price to $183 - 富途牛牛
Baird Financial Group Inc. Cuts Holdings in Icon Plc $ICLR - MarketBeat
ICON plc (ICLR): Assessing Valuation as CEO Transition Confirms Stability and 2025 Guidance - simplywall.st
Jefferies Downgrades Icon PLC(ICLR.US) to Hold Rating, Cuts Target Price to $175 - 富途牛牛
ICON Plc and Zealand Pharma’s Petrelintide Study: A Key Update for Investors - TipRanks
ICON plc’s Latest Study on Kedrion IVIG 10% for Chronic ITP: A Market Perspective - TipRanks
Will ICON’s (ICLR) Leadership Transition Reinforce Operational Continuity or Signal a Strategic Shift? - simplywall.st
Truist Financial Reaffirms Their Buy Rating on Icon (ICLR) - The Globe and Mail
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $220 to $225 - 富途牛牛
ICON plc Reaffirms 2025 Financial Guidance Amid CEO Transition - The Globe and Mail
Icon CEO Steve Cutler to retire, Barry Balfe to succeed - TipRanks
ICON Announces CEO Transition: Dr. Steve Cutler to Retire, Barry Balfe to Take Over - AInvest
ICON plc Announces CEO Changes, Effective October 1, 2025 - MarketScreener
ICON plc Appoints Barry Balfe to the Board - MarketScreener
ICON's Leadership Transition and Market Implications: Succession Strategy and Operational Continuity in Growth-Stage Biotech Firms - AInvest
ICON names Barry Balfe as new CEO effective October 1 By Investing.com - Investing.com Australia
Icon CEO Steve Cutler to Retire; Barry Balfe to Take Reins - MarketScreener
ICON names Barry Balfe as new CEO effective October 1 - Investing.com
ICON Promotes Barry Balfe to CEO Position - AInvest
Icon Promotes COO Barry Balfe to CEO Role - MarketScreener
ICON Announces CEO Transition Effective October 1, 2025 - TipRanks
ICON Announces CEO Transition - FinancialContent
ICON’s Strategic Positioning in the Evolving CRO Landscape - AInvest
ICON plc Announces Participation in September 2025 Investor Conferences - The Globe and Mail
Baird Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $224 - 富途牛牛
Healthcare Stocks to Watch: argenx, ICON, and Edwards Lifesciences with Long-Term Potential - AInvest
ICON plc to Participate at Upcoming Investor Conferences - PharmiWeb.com
ICON plc to Participate at Upcoming September 2025 Investor Conferences - BioSpace
ICON plc Announces Participation in Upcoming Investor Conferences - AInvest
ICON’s SWOT analysis: stock outlook amid industry headwinds and opportunities - Investing.com
Icon (ICLR) Stock Price, News & Analysis - MarketBeat
ICON’s Interim Financials Prompt Fresh Questions About Operational Agility and Efficiency for ICLR Investors - Yahoo Finance
Does ICON’s (ICLR) Interim Update Reveal New Clues About Efficiency in Clinical Research Outsourcing? - simplywall.st
ICON plc Releases Interim Financial Statements for 2025 - The Globe and Mail
AstraZeneca and Icon Plc’s Study on ATTR Amyloidosis: Key Insights for Investors - TipRanks
ICON Properties Plc (Malawi) declared a final dividend of 0.15 MWK per share - AfricanFinancials
ICON plc (ICLR) Investor Outlook: Navigating a 23% Upside Potential Amidst Market Volatility - DirectorsTalk Interviews
Earnings call transcript: ICON plc beats Q2 2025 earnings expectations - Investing.com
Citi Downgrades Icon PLC(ICLR.US) to Hold Rating, Cuts Target Price to $200 - 富途牛牛
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.20%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):